

# Amynas Announces Positive Search Report for PCT Patent Application

*The European Patent Office issued a positive International Search Report for the company's core NanoBiotics innovation, indicating a patent approval is likely.*

CHARLESTON, SC, UNITED STATES, June 3, 2026 /EINPresswire.com/ -- [Amynas](#), Inc. today announced the receipt of a positive International Search Report (ISR) from the European Patent Office (EPO) in relation to its PCT patent application covering the company's core NanoBiotics™ technology. The favorable assessment highlights the novelty and uniqueness of Amynas' nanofiber technology and represents an important milestone in strengthening its global intellectual property position.



Amynas logo



Receiving a positive ISR from the EPO is a strong validation of the originality of our technology. This feedback confirms that our core concepts are clearly differentiated from existing solutions."

*Lode Debrabandere, Amynas  
CEO*

The Amynas technology covered by this patent application solves two problems that increase the cost and morbidity of medical implants: 1) Rejection (or failure to rapidly and safely integrate) of implanted medical devices and 2) Infection, especially drug-resistant hospital-resident strains.

Amynas technology consists of two elements:

1) A device-agnostic envelope constructed from nanofibers, which mimics the body's native extracellular matrix. This biomimetic architecture promotes healthy, vascularized tissue growth, mitigating the scar tissue and

adhesion formation common with implants.

2) Antibiotics (rifampin & minocycline) embedded in the nanofibers, allowing gradual uniform

release, unlike coated antibiotics that release too quickly.

“Receiving a positive ISR from the EPO is a strong validation of the originality of our technology,” said Lode Debrabandere, CEO at Aynas. “This feedback confirms that the core concepts of our approach are clearly differentiated from existing solutions. Working closely with DLA Piper has been instrumental in articulating and protecting the inventive aspects of our surgical implants infection protection platform.”



A robust and defensible intellectual property portfolio is a cornerstone of Aynas' development and commercialization strategy. The positive international search results provide increased confidence as the company evaluates national phase entries and continues to advance its product pipeline.

Based on this positive report, Aynas expects to apply for a U.S utility patent for the same technology.

Venture Capital fund [Shepherd Ventures III](#) has agreed to lead the first scaling round (likely a Series A round) after Aynas' technology is on the market and ready to scale in its "beachhead" market of cardiovascular implantable electronic devices (CIEDs) and neurostimulator devices (NSDs).

A seed round of up to \$7.5 Million is now available to investors with attractive terms prior to a patent grant and FDA clearance.

### About Shepherd Ventures III

Shepherd Ventures III is a Venture Capital Fund specializing in assessing founding teams with an organizational development perspective. Like its predecessor Fund II, it expects that almost all portfolio companies will require a major pivot before succeeding and exiting. To this end, Shepherd Ventures III focuses on the leadership team as a unit, more than their resumes and the business plan, to ensure the team remains together and handles pivots well.

### About Aynas

Aynas is focused on developing innovative antibacterial technologies that leverage advanced materials and manufacturing methods to address unmet needs in infection prevention and control related to surgical implants. We focus on reducing hospital acquired infections in high risk patients with Cardiac Implantable Electronic Devices, Neurostimulator Devices, Orthopedic Implant Devices. The company is committed to applying rigorous science to create reliable,

high-quality solutions that support improved patient outcomes.

## Forward-Looking Statements

This press release contains forward-looking statements, including statements related to future stability results and product development. Actual results may differ materially due to various factors. Amynas undertakes no obligation to update these statements.

Robert Steven Kramarz

Intelliversity

+1 760-607-7655

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/913983575>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.